جستجوی مقالات مرتبط با کلیدواژه "sertraline" در نشریات گروه "شیمی"

One of the common clinical manifestations in patients with chronic liver disease is the symptom of pruritus which has been reported in about 80 to 100 %. In a subset of patients, nearly 10 to 20 %, the symptom becomes refractory and can lead to depression, inability to sleep, and even suicidal attempts. Aim of the study: The aim of the current study was to evaluate efficacy and safety of sertraline in treatment of pruritus associating chronic liver disease, diabetes mellitus, and atopic dermatitis.Patients and Sertraline was given at dose (75-100 mg/day) to all enrolled patients for 12 weeks. During this period patients were followed up for side effects. The highest rate was seen in chronic liver disease, patients followed by diabetes mellitus, and then by atopic dermatitis. Comparison of rate of satisfactory response among the study groups revealed no significant difference between chronic liver disease group and diabetes mellitus group (p = 0.643). Whereas, the rate was significantly higher in patients with chronic liver disease in comparison with control group (p = 0.033). Sertraline is an efficient and safe pharmacological agent for relief of pruritus not only in patients with chronic liver disease, in whom it has the best rate of satisfactory response, but also in other disorders such as diabetes mellitus and to a lesser extent atopic dermatitis.

The present study investigated the use of citrate-stabilized silver nanoparticles (Cit-AgNPs) as a colorimetric probe for the visual detection of three antidepressants imipramine, citalopram, and sertraline. Colorimetric approach relied on color change of Cit-AgNPs due to aggregation induced by antidepressants. UV-Vis spectroscopy, scanning electron microscopy (SEM), dynamic light scattering (DLS), zeta potential, and Fourier transform infrared spectroscopy (FT-IR) were used to characterize Cit-AgNPs before and after the reaction with antidepressants. It was found that surface plasmon resonance band of Cit-AgNPs centered at 400 nm was red shifted with concomitant color change from yellow to reddish brown, dark green, and red due to addition of imipramine, citalopram, and sertraline, respectively. Colorimetric response was linearly related to antidepressants concentration over the calibration range of 2-10 µg mL-1 with detection limits of 0.40, 0.25, and 0.39 µg mL-1 for imipramine, citalopram, and sertraline, respectively. Besides this, the proposed sensing strategy is capable of detecting the cited antidepressants in pharmaceutical preparations, spiked, and real deproteinized blood and urine samples without requiring light sensitive dyes, complicated equipment and organic co-solvents.

In this report, a new electrochemical sensor was developed for sertraline (STR) analysis. The sensor was prepared based on modified Pt electrode with graphene nanoparticles and molecular imprinting polymer (MIP) by coating a very thin layer of polymer onto a support. Through this approach, all of the binding sites of the polymer immobilized on the electrode surface are available for target molecules. The STR binding experiments indicated that the sensor modified by MIP have much higher adsorption ability than non−imprinted polymer (NIP) based sensor. Also, using of graphene in preparation of Pt electrode leads to a significant improvement in response of electrode because of their high electrical conductivity and large surface areas as the platform of the polymer that makes the graphene-MIP an excellent electrical transducer for direct electrical sensing. The cyclic voltammetry (CV) and differential pulse voltammetry (DPV) tests were used to evaluate the performance of the electrochemical sensor. Some parameters affecting the sensor performance such as MIP suspension, extraction pH and preconcentration time were optimized and under optimal conditions, the modified sensor with MIP-graphene showed linear responses with STR concentration in the range of 1.0×10-8 to 1.0×10-6 mol L-1 (R2 = 0.985) with a detection limit of 7.0×10-9 mol L-1. This developed sensor with the MIP was consequently capable of selective sensing of STR in human serum sample with recovery values in the range of 98.2-103.5%.

In this study a novel electrode was developed to simultaneous determination of serotonin (5-HT) and sertraline (ST) in the presence of uric acid based on a glassy carbon electrode modified by a composition of Fe3O4@MCM-48-SO3H and multi-wall carbon nanotubes (MWCNTs) (Fe3O4@MCM-48-SO3H/MWCNTs/GCE). The results showed that the modified electrode is a promising one for the simultaneous determination of 5-HT and ST in the presence of uric acid (UA) at optimized circumstances. Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques were used to study behavior of the modified electrode. The DPV results showed a linear relationship between 5-HT concentration and the oxidation peak current in the concentration ranges from 0.05 μM to 100 μM with a detection limit of 0.015 μM. For ST, a linear relationship between the concentration and the oxidation peak current in the ranges from 0.1 μM to 85 μM was obtained. The corresponding detection limit for ST was 0.025 μM. The Fe3O4@MCM-48-SO3H/MWCNTs/GCE was used for determination of 5-HT and ST in real samples like human blood serum and urine with reasonable outcomes.

The net analyte signal standard addition method was used for simultaneous spectrophotometric determination of sertraline and fluoxetine in pharmaceutical preparations. The method combines the advantages of the standard addition method with the net analyte signal concept to enable the extraction of information about an analyte from the spectra of multi-component mixtures. This method uses full spectrum realization and does not require calibration and prediction steps. Determination requires only a few measurements. The limit of detection for fluoxetine was 0.31 µg ml-1 and for sertraline was 0.20 µg ml-1. The root mean square error for fluoxetine was 0.45 and for sertraline was 0.39.